<DOC>
	<DOCNO>NCT01735890</DOCNO>
	<brief_summary>The objective study : - To compare safety profile CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg single oral administration healthy male volunteer - To compare pharmacokinetic profile CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg single oral administration healthy male volunteer</brief_summary>
	<brief_title>Phase Ⅰ Study Compare Safety , Pharmacokinetic Profiles CJ Amlodipine/Valsartan 10/160mg Tablet Novartis Exforge 10/160mg Tablet</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Years 2045 18 ≤ BMI &lt; 27kg/m² volunteer Subject take inducer inhibitor drug metabolism enzyme barbital within 28days prior study medication dose Subject symptom acute disease within 28days prior study medication dose Subject gastrointestinal disease surgery might significantly change absorption medicine Use prescription medication within 14 day prior study medication dose overthecounter medication include oriental medication within 7 day prior study medication dose Subject know hypersensitivity reaction amlodipine valsartan Subject follow condition laboratory test i. AST ( sGOT ) ALT ( sGPT ) &gt; Upper normal limit × 1.5 ii . Total bilirubin &gt; Upper normal limit × 1.5 iii . eGFR &lt; 50mL/min ⅳ. continue serum potassium concentration abnormal status ( baseline visit , &lt; 3.5mEq/L &gt; 5.5mEq/L ) Positive test result HBs Ab , HCV Ab , Syphilis regain test Drug abuse continue excessive use caffeine ( caffeine &gt; five cups/day ) , severe heavy smoker ( cigarette &gt; 10 cigarette per day ) alcohol ( alcohol &gt; 30g/day ) Subject take meal affect absorption , distribution , metabolism , excretion drug , especially grapefruit juice Clinically significant hypotension ( SBP &lt; 100mmHg , DBP ≤65mmHg ) hypertension ( SBP 100mmHg , DBP &lt; 65mmHg ) screening period Participation clinical investigation within 60days prior study medication dose Subjects whole blood donation within 60days , component blood donation within 20days blood transfusion within 30days prior study medication dose Subjects decision nonparticipation investigator 's review due laboratory test result excuse nonresponding request instruction investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>